Stem cells are biological cells that can differentiate into other types of cells, and are used for therapeutic purposes. Recent developments or advancements have paved the way for a plethora of potential therapies, due to which, therapies involving human embryonic stem cells are being widely adopted worldwide. Human embryonic stem cells have emerged as attractive candidates for cell-based therapies that are capable of restoring lost cell and tissue function. Furthermore, human embryonic stem cells (hESC) have a high potential for use in treatment and may become a standard of care for cardiac and malignant diseases.

Market Dynamics

Rise in incidence of cardiac and malignant diseases, increase in focus on the development of stem cell-based therapies, growing demand for regenerative medicines, and increasing support from government and private organizations are major factors expected to drive growth of the global human embryonic stem cells market during the forecast period.

For instance, in April 2021, Vertex Pharmaceuticals received the United States Food and Drug Administration (FDA) Fast Track Designation for VX-880, and the company initiated a clinical trial for VX-880 in patients who have type 1 diabetes with severe hypoglycemia and impaired hypoglycemic awareness.

In February 2020, Global Institute of Stem Cell Therapy and Research (GIOSTAR) announced the inauguration of a new stem cell / cancer research and therapy center in India. This facility represents the latest milestone in global expansion efforts spearheaded by GIOSTAR in India, Mexico, the United States, and numerous other countries.

Key features of the study

• The report provides in-depth analysis of the global human embryonic stem cells market, and provides market size (USD Bn) and compound annual growth rate (CAGR %) for the forecast period (2026–2033), considering 2025 as the base year.
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
• It profiles key players in the global human embryonic stem cells market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
• Key companies covered as a part of this study include Takara Bio Inc., ViaCyte Inc., PromoCell GmbH, Merck KgaA, PeproTech Inc., Astellas Pharma Inc., Thermo Fisher Scientific, Lineage Cell Therapeutics Inc., and STEMCELL Technologies Inc.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
• The global human embryonic stem cells market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human embryonic stem cells market.

Market Segmentation

• By Product
  • Regenerative Medicine
  • Stem Cell Biology Research
  • Tissue Engineering
  • Toxicology Testing
• By Region
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East & Africa
    • GCC Countries
    • Israel
    • Rest of Middle East & Africa
• Key Players
  • Takara Bio Inc.
  • ViaCyte Inc.
  • PromoCell GmbH
  • Merck KgaA
  • PeproTech Inc.
  • Astellas Pharma Inc.
  • Thermo Fisher Scientific
  • Lineage Cell Therapeutics Inc.
  • STEMCELL Technologies Inc.